Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1936 to 1950 of 7707 results

  1. Archimedes for biopsy of suspected lung cancer

      Status ...

    Medical technologies guidance
    Topic selection

  2. Actim Pancreatitis for diagnosing acute pancreatitis

      Status ...

    Diagnostics guidance
    Topic selection

  3. CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic

      Status ...

    Medical technologies guidance
    Topic selection

  4. PCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms

      Status ...

    Medical technologies guidance
    Topic selection

  5. Spartan RX point-of-care CYP2C19 test

      Status ...

    Diagnostics guidance
    Topic selection

  6. Healthy.io test for home testing of urine albumin to creatinine ratio

      Status ...

    Diagnostics guidance
    Topic selection

  7. FebriDx for C-reactive protein and myxovirus resistance protein A testing

      Status ...

    Diagnostics guidance
    Topic selection

  8. Helge for detecting haemolysis

      Status ...

    Diagnostics guidance
    Topic selection

  9. MolecuLight i:X for wound imaging

    The panel agreed the technology is not appropriate to be selected for guidance development as there is insufficient evidence.   ...

    Medical technologies guidance
    Topic selection

  10. NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds

      Status ...

    Medical technologies guidance
    Topic selection

  11. Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]

    Awaiting development [GID-TA11137] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915 ]

    Awaiting development [GID-TA10791] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy TSID 12015

    Awaiting development [GID-TA11551] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy [ID6354]

    Awaiting development [GID-TA11415] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]

    Awaiting development [GID-TA11366] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development